Insitro
How Insitro stacks up in AI Healthcare — funding data, key investors, and more.
Updated Mar 24, 2026Awaira Score
Out of 100
HQ
United States
Founded
2018
Raised
$743M
Stage
Series C
Team
300
Valuation
$2.2B
Post-money
Total Raised
$743M
All rounds
Awaira Score
73/100
Founded
2018
300 employees
Awaira estimate based on public data. Not financial advice.
About Insitro
Insitro is an AI-driven drug discovery company founded in 2018 that applies machine learning to accelerate pharmaceutical development. The company combines computational biology, artificial intelligence, and wet-lab experimentation to identify and validate drug targets more efficiently than traditional methods. Insitro's platform uses proprietary algorithms to analyze complex biological data,…
Is this your company? Claim it →Strengths & Risks
Strengths
Unicorn status with $2.2B valuation
Strong Awaira Score of 73/100
Growing team of 300 employees
Analysis based on publicly available data. Not investment advice.
Market Position
Insitro is a AI unicorn in the AI Healthcare sector. Founded in 2018, the company is currently at the Series C stage with a team of approximately 300 employees. With $743M in total disclosed funding, Insitro has demonstrated the ability to attract institutional capital. The company competes with 3 other tracked AI Healthcare companies on Awaira, including Butterfly Network and Tempus.
Key Numbers
Awaira Score
73/100
Valuation
$2.2B
Total Funding
$743M
Founded
2018
Employees
300
Stage
Series C
Funding Velocity
3
Total Rounds
$124.33M
Avg Round Size
2.8yr
Funding Span
Insitro raised 3 rounds over 2.8 years, averaging $124.33M per round — a pace of roughly one round every 11 months.
Why Track Insitro?
Insitro holds unicorn status in the AI Healthcare space, placing it among the highest-valued private AI companies globally.
Among 3 tracked competitors, Insitro ranks #3 by valuation — a metric investors and analysts use to gauge market standing.
Tracking Insitro on Awaira provides real-time updates on funding rounds, investor activity, and competitive moves in the AI Healthcare market.
Competitor Comparison
| Metric | ★Insitro | Butterfly Network | Tempus | Alan |
|---|---|---|---|---|
| Awaira Score | 73/100 | 85/100 | 84/100 | 83/100 |
| Total Raised | $743M | $370M | $1.05B | $750M |
| Valuation | $2.2B | $957M | $8.1B | $5.83B |
| Stage | Series C | Public | Public | Series D |
| Founded | 2018 | 2011 | 2015 | 2016 |
| Employees | 300 | 500-1000 | 2500 | 500-1000 |
| Country | 🇺🇸 | 🇺🇸 | 🇺🇸 | 🇫🇷 |
Investors in Insitro
Funding Rounds
InactiveLed by Andreessen Horowitz
$200M
Oct 2021
Led by Andreessen Horowitz
$143M
Jan 2020
Led by Andreessen Horowitz
$30M
Jan 2019
Open Positions at Insitro
View all jobs →Insitro Latest News
Compare Insitro
See how Insitro stacks up against competitors in valuation, funding, team size, and Awaira Score.
Founded Same Year (2018)
More from United States
🇺🇸 View all AI companies in United States →Alternatives
View all alternatives to Insitro →